Claims for Patent: 7,863,297

Summary for Patent: 7,863,297

Title:	Methods of using 4-(amino)-2-(2,6-dioxo(3-piperidly))-isoindoline-3-dione for the treatment of myelodysplastic syndromes
Abstract:	Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active ingredient, and/or the transplantation of blood or cells. Specific second active ingredients are capable of affecting or blood cell production. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Inventor(s):	Zeldis; Jerome B. (Princeton, NJ)
Assignee:	Celgene Corporation (Summit, NJ)
Application Number:	11/985,032
Patent Claims:	1. A method of treating a myelodysplastic syndrome, which comprises (a) administering to a patient in need thereof about 0.1 mg per day to about 10 mg per day of 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione of formula: ##STR00009## or a pharmaceutically acceptable salt, solvate or stereoisomer thereof for a period of time followed by a period of rest; and (b) repeating step (a). 2. The method of claim 1, wherein the compound is a pharmaceutically acceptable salt. 3. The method of claim 1, wherein the compound is a pharmaceutically acceptable solvate. 4. The method of claim 1, wherein the stereoisomer is an enantiomerically pure R isomer or S isomer. 5. The method of claim 1, which further comprises (c) administering a therapeutically effective amount of a second active agent for a period of time followed by a period of rest; and (d) repeating step (c). 6. The method of claim 5, wherein the second active agent is capable of improving blood cell production. 7. The method of claim 5, wherein the second active agent is a cytokine, hematopoietic growth factor, an anti-cancer agent, an antibiotic, a proteasome inhibitor, or an immunosuppressive agent. 8. The method of claim 5, wherein the second active agent is etanercept, imatinib, anti-TNF-.alpha. antibodies, infliximab, G-CSF, GM-CSF, EPO, topotecan, pentoxifylline, ciprofloxacin, irinotecan, vinblastine, dexamethasone, IL2, IL8, IL18, Ara-C, vinorelbine, isotretinoin, 13-cis-retinoic acid, arsenic trioxide, or a pharmacologically active mutant or derivative thereof. 9. The method of claim 1, wherein the myelodysplastic syndrome is refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or chronic myelomonocytic leukemia. 10. The method of claim 1, wherein the compound is administered orally. 11. The method of claim 10, wherein the compound is administered in the form of a capsule or tablet. 12. The method of claim 1, wherein the number of cycle is from one to twelve cycles. 13. The method of claim 1, the compound is administered in an amount of from about 0.1 to about 10 mg per day for 21 days every 28 days for sixteen or twenty-four weeks. 14. The method of claim 1, wherein the compound is administered in an amount of from about 0.1 mg per day to about 10 mg per day for 21 days followed by seven days of rest in a 28 days cycle. 15. The method of claim 1, wherein the compound is administered orally in an amount of 0.1 mg, 1 mg, 2 mg, 2.5 mg, 5 mg or 10 mg as a capsule per day. 16. The method of claim 1, wherein the 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione is administered. 17. The method of claim 5, wherein the second active agent is azacytidine.

Details for Patent 7,863,297

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2022-10-15
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2022-10-15
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2022-10-15
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2022-10-15
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007		2022-10-15
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	09/14/2017		2022-10-15
Immunex Corporation	ENBREL	etanercept	Injection	103795			2022-10-15